GLOBAL BLOOD THERAPEUTICS Stock News

Global Blood Therapeutics, Inc. (GBT) CEO Ted Love on Q4 2020 Results - Earnings Call Transcript

With the trading day more than halfway over, the broad markets saw a huge pull back on Thursday.

Global Blood (GBT) reports a wider-than-expected loss in the fourth quarter of 2020 while revenues beat estimates.

Global Blood (GBT) delivered earnings and revenue surprises of -3.09% and 6.18%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Shares of Global Blood Therapeutics (NASDAQ:GBT) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 37.11% over the past year to ($1.

Achieved Oxbryta ® (voxelotor) net revenues of $41.3 million in the fourth quarter and  $123.8 million for full year 2020

Global Blood (GBT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report fourth quarter and full year 2020 financial resu

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on February 1, 2021, the compensation committee of GBT's board

Global Blood's (GBT) Marketing Authorization Application for the label expansion of Oxbryta tablets has been accepted by the European Medicines Agency.

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the European Medicines Agency (EMA) has completed the validation

Global Blood Therapeutics ended 2020 with a nearly 40% drop in its share price. The pandemic negatively affected the number of Oxbryta prescriptions and therefore Oxbryta sales.

Since 2017, GBT has come a long way to gain Oxbryta approval for treating sickle cell disease. After over 100% capital gains, the stock gave up some profits as the market is sizing up Oxbryta's sales

Final 72-Week Analyses of Phase 3 HOPE Study Demonstrat e Durable Improvements in Hemoglobin Levels and Significant Improvements in Overall Health Status

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the initiation of an early access program for voxelotor, in Europe an